Navigation Links
Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
Date:3/28/2011

l program including 1st line multiple myeloma, combination studies, lymphoma and other malignancies.

About Multiple Myeloma

Multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone marrow. In the United States, more than 50,000 people are living with multiple myeloma and approximately 20,000 new cases are diagnosed annually.(i) Worldwide, more than 180,000 people are living with multiple myeloma and approximately 86,000 new cases are diagnosed annually.(ii)

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a selective proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma in various settings and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Forward Looking Statements

This press release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws.  These forward-looking statements include, without limitation, statements regarding the clinical development
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
2. VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
5. Endo Pharmaceuticals Appoints Dr. David Nash to Board of Directors
6. Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
7. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
8. MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
11. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that they ... Russian pharmaceutical company, to develop and commercialize nemonoxacin (Taigexyn ... , Turkey and other members ... antibiotic for the treatment of bacterial infections including those ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Histogen, ... the products of cells grown under simulated embryonic conditions, ... license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic ... , This agreement is an amendment to ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an ... products to serve the wound care market. , Free ... Alliqua was restructured with a seasoned management team and ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 iLab Solutions, the ... as the new Director of Product Strategy. In this role, ... as iLab sub-teams to guide in the development of iLab ... provides the maximum possible benefit to the scientific community by ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2
... U.S. Department of Energys Brookhaven National Laboratory have developed ... and micrometer-sized particles. The method, based on designed DNA ... to manipulate the structure and therefore the properties ... be of interest to industry. For example, such fine-tuning ...
... 12 BioReliance Corporation, a,leading contract services ... contracted with Gentronix to offer their,GreenScreen HC ... of BioReliance,s portfolio of,genotoxicity screening services. GreenScreen ... pharmaceutical companies to test for genotoxic potential,earlier ...
... Inc. (Nasdaq:,PPDI) today announced Daniel G. Darazsdi has ... position on October 1. Mr. Darazsdi, 47, ... a $34 billion diversified technology and manufacturing,leader, where ... CFO of finance,transformation and operations. Over the years ...
Cached Biology Technology:New DNA-based technique for assembly of nano- and micro-sized particles 2BioReliance Launches Next-Generation Genotoxicity Screening Service 2PPD Names Daniel Darazsdi as Chief Financial Officer 2PPD Names Daniel Darazsdi as Chief Financial Officer 3
(Date:7/9/2014)... shows that the population is 3.79 million breeding ... Adlie penguins have long been considered a key ... of climate change and fishing in the Southern ... from Stony Brook University and University of Minnesota ... monitoring of Adlie penguins across their entire breeding ...
(Date:7/9/2014)... may be on the verge of an economy driven by ... than coal and is undergoing a production boom. It has ... recent research is casting serious doubts over just how climate-friendly ... Engineering News (C&EN), the weekly news magazine of the ... senior correspondent at C&EN, explains that when burned as a ...
(Date:7/9/2014)... candidate developed by researchers at the NIH,s ... and its collaborators to treat sickle cell ... BioScience business. The drug candidate, Aes-103, is ... underlying molecular mechanism of sickle cell disease. ... activities required for regulatory approval and commercialization. ...
Breaking Biology News(10 mins):New study finds that Adélie penguin population is on the rise 2New study finds that Adélie penguin population is on the rise 3First drug candidate from NIH program acquired by biopharmaceutical company 2First drug candidate from NIH program acquired by biopharmaceutical company 3First drug candidate from NIH program acquired by biopharmaceutical company 4
... span of a common rat, the 10 to 30 year ... to East Africa, is impressive. And compared to the human ... to aging, maintaining high activity, bone health, reproductive capacity, and ... in Israel and the United States is working to uncover ...
... during pregnancy are uncommon, but the prevalence of heart disease ... more women delay pregnancy until they are older. These women, ... tend to have higher cholesterol levels and are at greater ... research has shown that the heart typically functions better during ...
... summer season is in full swing, many of us will be ... have some unwanted guests in the form of mosquitoes. Mosquitoes ... Syed, a mosquito biologist with the University of Notre Dame,s Eck ... determining how they do it. In short, it,s because of ...
Cached Biology News:Naked mole rat may hold the secret to long life 2UCLA study looks at why heart attacks cause so much more damage in late pregnancy 2Mosquitoes -- how we smell is why they bite, research shows 2
... sensitive reagent for the detection of inorganic ... of recombinant E. coli phosphate-binding protein labeled ... to changes in its environment.How it worksBinding ... rapid and tight (Kd ~ 0.1 M), ...
... Costar strip ejector is a unique product ... strips from their holder. Linkage: This CLS ... to easily match Cornings product number. If ... the old Sigma-Aldrich number (Z71,314-7) or contact ...
... hood ventilates and purifies hazardous chemical ... exhaust. Bonded charcoal filters remove most ... clearance (with access shield open) accommodates ... options include final HEPA filter, work ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
Biology Products: